Concepedia

Kelly Jacques

KJ

Statistics

Publications

7

Citations

524

H-Index

7

Active since

2013

Affiliations

AstraZeneca (United States)(Current)

University of North Texas

AstraZeneca (United Kingdom)

DEVCOM Army Research Laboratory

Kelly Jacques is an author at AstraZeneca (United States) specializing in molecular oncology, materials engineering, and tribology.

Publications per year

2013–2023

7

Publications

7

EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex

Jessie Hao-Ru Hsu, Timothy Rasmusson, James Robinson et al. · Cell chemical biology · 2019 · 197 citations · Full text

Medicine, Molecular Biology, Molecular Genetics +5

Discovery and Mechanistic Study of a Small Molecule Inhibitor for Motor Protein KIFC1

Jiaquan Wu, Keith Mikule, Wenxian Wang et al. · ACS Chemical Biology · 2013 · 123 citations

Life Sciences, Cell Biology, Oncology +17

Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors

Barry R. Davies, Nin Guan, Armelle Logié et al. · Molecular Cancer Therapeutics · 2015 · 73 citations

Medicine, Oncology, Pharmacology +17

BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors

Garrett W. Rhyasen, Yi Yao, Jingwen Zhang et al. · PLoS ONE · 2018 · 54 citations · Full text

Medicine, Molecular Biology, Oncology +17

Effect of Water Incorporation on the Lubrication Characteristics of Synthetic Oils

Kelly Jacques, Tasha Joy, Asghar Shirani et al. · Tribology Letters · 2019 · 35 citations

Engineering, Materials Engineering, Mechanical Engineering +16

1–5 of 7